Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fitusiran in severe hemophilia A or B
NCT05662319Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Feb 2023
- Primary completion
- Mar 2027
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 17
01
Overview
Phase 3, open-label, single-arm trial of fitusiran in hemophilia A and hemophilia B (HB), sponsored by Sanofi. Primary endpoint: Annualized Bleeding Rate. Started Feb 2023; status: active, not recruiting.
02
Drugs
fitusiran
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT05662319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05662319.